Immunosuppression confers markedly elevated cSCC risk, with transplant recipients experiencing 65- to 100-fold higher ...
Betts, MD, discusses how discharging patients as early as day 5 after stem cell transplant has proved feasible and improves quality of life. Brian C. Betts, MD, Vice Chair of Strategic Initiatives for ...
FCA lymphodepletion produced dose-limiting toxicities, including grade 3 autoimmune hepatitis and fatal hyperinflammatory ...
Early termination after 68 randomizations reflected a 61% serious AE rate and 19% treatment-related deaths with radiotherapy, ...
In an interview with Targeted Oncology, Eunice S. Wang, MD, of Roswell Park Comprehensive Cancer Center, discussed which ...
Wang, MD, of Roswell Park Comprehensive Cancer Center, discussed the evolving role of measurable residual disease (MRD) as ...
Dr. Monty Pal discusses how the increasing use of adjuvant immunotherapy has introduced new considerations for the management ...
Joseph Mikhael, MD, MEd, highlights the clinical and logistical advantages of the novel on-body injector developed for the ...
KOMET-007 shows ziftomenib plus venetoclax/azacitidine drives deep MRD-negative remissions in R/R AML, with manageable ...
Dr. Monty Pal summarizes his practical first-line treatment algorithm for advanced renal cell carcinoma (RCC), highlighting ...
Joseph Mikhael, MD, MEd, describes the impact of the FDA's approval of subcutaneous isatuximab with an on-body injector device. Joseph Mikhael, MD, MEd, professor in the Applied Cancer Research and ...
KOMET-007 tests ziftomenib with venetoclax and azacitidine in relapsed/refractory AML, selecting 600 mg to boost responses ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results